CN107847470A - 用于治疗、预防和诊断癌症与其它增殖性疾病的组合物和方法 - Google Patents

用于治疗、预防和诊断癌症与其它增殖性疾病的组合物和方法 Download PDF

Info

Publication number
CN107847470A
CN107847470A CN201480075495.2A CN201480075495A CN107847470A CN 107847470 A CN107847470 A CN 107847470A CN 201480075495 A CN201480075495 A CN 201480075495A CN 107847470 A CN107847470 A CN 107847470A
Authority
CN
China
Prior art keywords
agx51
cancer
cells
compound
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480075495.2A
Other languages
English (en)
Chinese (zh)
Inventor
W·A·加兰德
J·查达瑞
G·斯托勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ogi Anji Nicks Ltd By Share Ltd
Original Assignee
Ogi Anji Nicks Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ogi Anji Nicks Ltd By Share Ltd filed Critical Ogi Anji Nicks Ltd By Share Ltd
Publication of CN107847470A publication Critical patent/CN107847470A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480075495.2A 2013-12-13 2014-12-14 用于治疗、预防和诊断癌症与其它增殖性疾病的组合物和方法 Pending CN107847470A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361916116P 2013-12-13 2013-12-13
US61/916,116 2013-12-13
US201461965776P 2014-02-06 2014-02-06
US61/965,776 2014-02-06
PCT/US2014/070221 WO2015089495A2 (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Publications (1)

Publication Number Publication Date
CN107847470A true CN107847470A (zh) 2018-03-27

Family

ID=53371974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480075495.2A Pending CN107847470A (zh) 2013-12-13 2014-12-14 用于治疗、预防和诊断癌症与其它增殖性疾病的组合物和方法

Country Status (6)

Country Link
EP (1) EP3079680A4 (https=)
JP (2) JP2017506257A (https=)
CN (1) CN107847470A (https=)
AU (1) AU2014361814A1 (https=)
MX (1) MX2016007748A (https=)
WO (1) WO2015089495A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164617A (zh) * 2018-08-10 2021-07-23 托马斯·梅尔希奥·霍曼 用于调制α-酮戊二酸(2OG)依赖型加氧酶并作为其功能替代的化合物
CN114480490A (zh) * 2021-12-31 2022-05-13 四川省医学科学院·四川省人民医院 一种构建视网膜新生血管性疾病动物模型的方法
CN115487358A (zh) * 2022-08-05 2022-12-20 核工业四一六医院 一种用于软骨组织修复的凝胶复合支架及制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) * 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
EP3760614B8 (en) * 2019-07-02 2022-04-27 Universität Heidelberg Chemical inhibitors of id proteins for the treatment of cancer and other diseases
WO2021067393A1 (en) * 2019-10-01 2021-04-08 Memorial Sloan Kettering Cancer Center SMALL MOLECULE INHIBITORS OF Id PROTEINS
CN113627763B (zh) * 2021-07-30 2023-12-01 厦门大学 一种风险量化评估模型建立方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051801A2 (en) * 2007-10-16 2009-04-23 Angiogenex Chemical inhibitors of inhibitors of differentiation
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000036A1 (en) * 2010-06-30 2012-01-05 Garvan Institute Of Medical Research Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051801A2 (en) * 2007-10-16 2009-04-23 Angiogenex Chemical inhibitors of inhibitors of differentiation
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAIDEEP CHAUDHARY ET AL.: "A novel small molecule inhibitor of Id proteins(AGX-51) blocks cell survival", 《THE FASEB JOURNAL SUPPLEMENT》 *
PUBCHEM: "SID 79254004", 《URL：HTTPS://PUBCHEM.NCBI.NLM.NIH.GOV/SUBSTANCE/79254004》 *
TIMMY MANI ET AL.: "Probing Binding and Cellular Activity of Pyrrolidinone and Piperidinone Small Molecules Targeting the Urokinase Receptor", 《CHEMMEDCHEM》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164617A (zh) * 2018-08-10 2021-07-23 托马斯·梅尔希奥·霍曼 用于调制α-酮戊二酸(2OG)依赖型加氧酶并作为其功能替代的化合物
CN114480490A (zh) * 2021-12-31 2022-05-13 四川省医学科学院·四川省人民医院 一种构建视网膜新生血管性疾病动物模型的方法
CN115487358A (zh) * 2022-08-05 2022-12-20 核工业四一六医院 一种用于软骨组织修复的凝胶复合支架及制备方法
CN115487358B (zh) * 2022-08-05 2023-05-30 核工业四一六医院 一种用于软骨组织修复的凝胶复合支架及制备方法

Also Published As

Publication number Publication date
EP3079680A4 (en) 2017-11-22
EP3079680A2 (en) 2016-10-19
AU2014361814A1 (en) 2016-07-28
MX2016007748A (es) 2017-07-28
WO2015089495A2 (en) 2015-06-18
JP2019203028A (ja) 2019-11-28
WO2015089495A3 (en) 2015-11-12
JP2017506257A (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
CN107847470A (zh) 用于治疗、预防和诊断癌症与其它增殖性疾病的组合物和方法
Adjuto-Saccone et al. TNF-α induces endothelial–mesenchymal transition promoting stromal development of pancreatic adenocarcinoma
Zhang et al. Polo-like kinase 4’s critical role in cancer development and strategies for Plk4-targeted therapy
Bayrer et al. LRH-1 mitigates intestinal inflammatory disease by maintaining epithelial homeostasis and cell survival
Kim et al. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer
JP2023098947A (ja) 損傷および／または老化細胞の同定および排除
Joachim et al. Protective effects on the retina after ranibizumab treatment in an ischemia model
JP2016540738A (ja) 転移性前立腺癌の治療
CA2875918A1 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US20180110837A1 (en) Methods and assays relating to macrophage differentiation
EP2836232A2 (en) Treatment of ischemic retinopathies
US20150301067A1 (en) Methods and assays for facioscapulohumeral muscular dystrophy
CN102483404A (zh) 鉴定用于治疗癌症的化合物的方法
WO2014082085A1 (en) Use of itk inhibitors for the treatment of cancer
ES2905360T3 (es) Composiciones y métodos para detectar, tratar y prevenir enfermedades y trastornos
JP2016511766A (ja) Ｃａｉｘ階層化に基づく癌治療
Su et al. Endocan blockade suppresses experimental ocular neovascularization in mice
US20220280590A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
US20200216906A1 (en) Methods and compositions relating to the diagnosis and treatment of cancer
Ray et al. Lung cancer therapeutics that target signaling pathways: an update
US20080221014A1 (en) Method of Diagnosing and Treating Glioma
Tada et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma
US20190117596A1 (en) Ty-52156 compounds for the treatment of cancer
WO2008046529A1 (en) Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule
US20200023038A1 (en) Method of treating neoplasias

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180327

WD01 Invention patent application deemed withdrawn after publication